SS&C(SSNC) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - SS&C reported record adjusted revenue of $1.655 billion for Q4 2025, an increase of 8% year-over-year [5] - Adjusted diluted earnings per share (EPS) reached $1.69, reflecting an 18% increase [5] - Adjusted consolidated EBITDA was a record $651 million, up 9%, with an EBITDA margin of 39.3% [5][12] - Cash from operating activities for the full year was $1.745 billion, up 26% year-over-year [7] Business Line Data and Key Metrics Changes - GIDS experienced a revenue growth of 13.2%, while GlobeOp saw a 9.6% increase [6] - Intralinks showed modest growth in Q4, with expectations for momentum in 2026 [6] - The healthcare business faced challenges, but management remains optimistic about long-term growth opportunities [21][23] Market Data and Key Metrics Changes - The company is focusing on international growth opportunities, particularly in Australia with GlobeOp [6] - The alternative fund administration business showed exceptional growth in assets under administration, with expectations for continued growth in 2026 [27] Company Strategy and Development Direction - SS&C is leveraging AI and automation as a competitive advantage, believing it will drive long-term growth and profitability [4][19] - The company is prioritizing share repurchases and is optimistic about the early progress of the Calastone acquisition [8][19] - Management emphasized the importance of maintaining strong client relationships and expanding service offerings [10] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the healthcare sector but remains confident in the market's potential [21][23] - The company expects to maintain strong organic growth throughout 2026, with a focus on recurring revenue and long-term client partnerships [33] - Management is optimistic about the impact of AI on operational efficiency and competitive positioning [10][35] Other Important Information - SS&C ended Q4 with $462 million in cash and cash equivalents and $7.5 billion in gross debt, resulting in a net leverage ratio of 2.8 times [15] - The company plans to maintain capital expenditures at 4.4%-4.8% of revenues and continue share buybacks similar to 2025 levels [16] Q&A Session Summary Question: What drove the weakness in the healthcare business? - Management indicated that healthcare is a long-term play and noted the challenges of quarter-to-quarter comparisons, citing large license sales in the previous year [21][22] Question: Update on the Elevance relationship? - Management stated that DomaniRx is ready for onboarding, but highlighted the challenges of navigating relationships within large healthcare organizations [24] Question: Insights on alternative fund administration growth? - Management confirmed strong organic growth in the alternative fund administration sector, attributing part of the growth to the acquisition of Curo Fund Services [27] Question: Outlook for the intelligent automation business? - Management expressed optimism for the intelligent automation business, noting that it is a key area for innovation and growth [28][30] Question: Expectations for organic growth in wealth management? - Management is optimistic about the wealth management business, particularly the Black Diamond platform, which is expected to continue driving growth [38] Question: M&A environment insights? - Management is actively looking for acquisition opportunities and believes they are well-positioned to pursue larger acquisitions if the right opportunity arises [39]